Hepatocellular Cancer Clinical Trial
— pregabalinOfficial title:
Effect of Preoperative Administration of Oral Pregabalin on the Postoperative Analgesia in Patients Scheduled for Radiofrequency Ablationof Focal Lesions in the Liver
The study aimed to investigate the preemptive analgesia efficacy of of preemptive pregabalin for the postoperative pain management after radiofrequency ablation (RFA) of liver cancer.
| Status | Recruiting |
| Enrollment | 100 |
| Est. completion date | December 2019 |
| Est. primary completion date | December 2019 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 75 Years |
| Eligibility |
Inclusion Criteria: - HCC patients, Child A, B, scheduled for Radiofrequency ablation of HCC. Exclusion Criteria: - Encephalopathy, Renal impairment |
| Country | Name | City | State |
|---|---|---|---|
| Egypt | Tanta university - faculty of medicine | Cairo | Elgharbia |
| Lead Sponsor | Collaborator |
|---|---|
| Sherief Abd-Elsalam |
Egypt,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | visual analogue pain scale (VAS Pain) post operatively | Amplitude of pain postoperatively | 2 weeks |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03971201 -
A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion
|
Phase 2 | |
| Recruiting |
NCT04484636 -
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)
|
N/A | |
| Recruiting |
NCT05489250 -
The PLATON Network
|
||
| Completed |
NCT01967823 -
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
|
Phase 2 | |
| Terminated |
NCT00878215 -
Clinical Application of Image-Guided Liver Surgery
|
Phase 2 | |
| Completed |
NCT04212286 -
Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC
|
N/A | |
| Recruiting |
NCT05992220 -
Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion
|
Phase 2 | |
| Completed |
NCT02073435 -
A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation
|
||
| Active, not recruiting |
NCT01522937 -
A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer
|
Phase 2 | |
| Terminated |
NCT05061537 -
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT04166240 -
Measuring and Improving the Safety of Test Result Follow-Up
|
N/A | |
| Withdrawn |
NCT02288507 -
Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
|
Phase 1 | |
| Terminated |
NCT03026803 -
A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04682847 -
Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
|
||
| Active, not recruiting |
NCT05100082 -
Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma
|
||
| Active, not recruiting |
NCT03195699 -
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
|
Phase 1 | |
| Completed |
NCT02616692 -
HCC Patient Preferences in Japan
|
N/A | |
| Active, not recruiting |
NCT03132792 -
AFPᶜ³³²T in Advanced HCC
|
Phase 1 | |
| Recruiting |
NCT01849588 -
Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C
|
Phase 4 | |
| Completed |
NCT00997022 -
Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients
|
Phase 1 |